Data Bytes: preclinical IPO performance trending up
The last 18 months have seen a trend towards positive aftermarket performance for preclinical IPOs
IPOs by preclinical biotechs since 2013 had largely been hit or miss until the past 18 months, when a trend toward positive aftermarket performance has emerged.
